drugset
drugset / Trial / NCT01195207

A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma

NCT01195207 ↗

Phase 1 Completed 79 enrolled Centocor, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

This is a phase 1, safety study of CNTO 3157 in healthy subjects and subjects with asthma.

Timeline

Start
2010-06
Primary completion
—
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTO 3157 Monoclonal antibody 0.003 mg/kg Intravenous
Subject CNTO 3157 Monoclonal antibody 0.01 mg/kg Intravenous
Subject CNTO 3157 Monoclonal antibody 0.03 mg/kg Intravenous
Subject CNTO 3157 Monoclonal antibody 0.1 mg/kg Intravenous
Subject CNTO 3157 Monoclonal antibody 0.3 mg/kg Intravenous
Subject CNTO 3157 Monoclonal antibody 1 mg/kg Intravenous
Subject CNTO 3157 Monoclonal antibody 3 mg/kg Intravenous
Subject CNTO 3157 Monoclonal antibody 10 mg/kg Intravenous

Indications

asthma